29.08 -0.15 (-0.51%)
After hours: 7:56PM EST
|Bid||28.75 x 1300|
|Ask||0.00 x 800|
|Day's Range||28.31 - 30.09|
|52 Week Range||16.74 - 59.25|
|Beta (3Y Monthly)||2.33|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
New York Governor Andrew Cuomo prioritized legalizing recreational marijuana use in the state. Yahoo Finance's Julie Hyman, Adam Shapiro, Rick Newman, Liz Young, Director of Market Strategy, BNY Mellon Investment Management and Marijuana Business Daily Founding Editor and Vice President Chris Walsh discuss.
In the latest trading session, Canopy Growth Corporation (CGC) closed at $29.21, marking a -0.54% move from the previous day.
OTCQX: TRSSF), NETA NJ LLC (“NETA”), has been selected by the State of New Jersey Department of Health to apply for final approval to operate a vertically integrated Alternative Treatment Center (ATC), which would permit it to cultivate, process and sell medical cannabis in the state. The State of New Jersey received a total of 146 applications to cultivate, process and sell medical cannabis.
Although it has risen from recent lows, the pain for Aphria (NYSE:APHA) stock continues. With the credibility of Aphria’s management called into question by short-seller research reports, APHA has now fallen below Cronos (NASDAQ:CRON) in market cap. With APHA trading at a much lower valuation than its peers, the case for a risky contrarian play in Aphria stock only grows stronger.
Marijuana stocks like Cronos Group (NASDAQ:CRON) stock have spent 2018 in the hype cycle. The hype cycle is a term common to technology investors. Now, just as things settle down, Altria (NYSE:MO), formerly the U.S. unit of Philip Morris, is paying $1.8 billion to get 45% of Cronos, a medical marijuana company based in Canada.
CORAL GABLES, FL / ACCESSWIRE / December 18, 2018 / Marijuana stocks have seen a lot of excitement this year. As 2019 gets closer, Premier Health Group (OTC: PHGRF) (CSE: PHGI) , Aurora Cannabis (NYSE: ...
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / U.S. equities extended losses on Monday as investors await details from the Federal Reserve's final policy meeting of 2018 on Wednesday. The Dow Jones Industrial ...
Cronos executed a potentially transformative deal with tobacco giant Altria (NYSE:MO). Indeed, I’m somewhat surprised by the reaction, in terms of both Cronos stock and pot stocks on the whole. As rumors of a deal flew earlier this month, I wrote that an executed agreement would be transformative for CRON stock, and the industry.
Not only has it caused a stir with US pot stocks but Canadian marijuana stocks are also seeing more activity this week. With marijuana stocks in focus, here are 4 pot stocks to watch this month. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced earlier this month that as a part of its growth strategy to cover the major verticals associated with primary care, it has signed a binding Letter of Intent to acquire a Vancouver, British Columbia based pharmacy.
When the going gets tough in the Canadian marijuana market, there could be a surprising winner.
Congress passed the Farm Bill this week, which President Trump is expected to sign, opening the floodgates for rapid growth in the hemp-derived CBD product market in the U.S.
Canada’s cannabis leader is currently Aurora Cannabis (NYSE:ACB). This is a well established and rapidly growing cannabis company. Namely, alcoholic beverage giant Constellation Brands (NYSE:STZ) and Marlboro cigarette maker Altria (NYSE:MO) have both made billion dollar investments into Canadian cannabis companies Canopy Growth (NYSE:CGC) and Cronos (NASDAQ:CRON), respectively.